This website uses cookies

This websites contains videos from YouTube. This company uses cookies (third party cookies). If you do not want them to use these cookies, you can indicate so here. However, this does mean that you will not be able to watch videos on this website. We also make use of our own cookies in order to improve our website. We don't share our data with other parties. Which cookies are involved?

This website uses cookies to enable video and to improve the user experience. If you do not want to accept these cookies, indicate so here. Which cookies are involved?

Ga direct naar de inhoud, het hoofdmenu, het servicemenu of het zoekveld.

Back to overview

Rosemarie de Haan group

Haan, Rosemarie de.jpg

Rosemarie de Haan

Ph.D. student

Personal details


My PhD project involves clinical and translational research. The main goal is to determine the safety and tolerability of olaparib (a PARP inhibitor) combined with radiotherapy in different groups of patients: non-small-cell lung cancer, head and neck squamous cell carcinoma and breast cancer patients. PARP is involved in single strand DNA repair. PARP inhibition leads to radiosensitization through the conversion of irradiation induced single strand DNA breaks into for the cell lethal double strand DNA breaks upon replication.

The translational research includes pharmacokinetic and pharmacodynamic analysis within the trial; as well as some in vitro cell culture studies.

Share this page